Regulation of cell adhesion by PAI-1.
Type I plasminogen activator inhibitor (PAI-1) is the primary inhibitor of tissue- and urokinase-type plasminogen activators. It circulates in plasma complexed with vitronectin (VN), the primary PAI-1 binding protein. The somatomedin B (SMB) domain of VN contains both the high affinity PAI-1 binding site and the specific site for urokinase plasminogen activator receptor (uPAR). PAI-1 is able to regulate uPAR-mediated cell adhesion by competing with uPAR for VN binding. Binding of PAI-1 to SMD may also affect integrin-mediated cell adhesion to VN by hindering integrin binding to the RGD sequence adjacent to the uPAR binding site.
Loskutoff
D J
DJ
Department of Vascular Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Curriden
S A
SA
Hu
G
G
Deng
G
G
D000818:Animals; D001665:Binding Sites; D002448:Cell Adhesion; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000502:physiology*; D011956:Receptors, Cell Surface / Q000502:physiology; D055293:Receptors, Urokinase Plasminogen Activator; D019096:Vitronectin / Q000502:physiology
C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D019096:Vitronectin